Literature DB >> 8005231

Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases.

S Molica1, M Brugiatelli, V Callea, F Morabito, D Levato, F Nobile, A Alberti.   

Abstract

Fifty-three patients affected with B-cell chronic lymphocytic leukemia (CLL) younger than 50 years and observed in two hematological institutions have been retrospectively evaluated in order to verify whether this disease has different clinico-hematological features at presentation and different prognosis as compared to older cases. In our experience young cases with B-CLL diagnosis, confirmed by immunophenotype in 90.5% of patients, accounted for 7.1% of the whole CLL population. Sex distribution, mean peripheral lymphocyte count, platelet count, distribution among Rai's and Binet's stages, total tumor mass (TTM) score, histological pattern of bone marrow infiltration and lymphocyte doubling time (LDT) were similar to a series of 201 CLL cases older than 50 years. Only hemoglobin mean level was significantly higher in younger patients (13.1 +/- 2.1 vs 12.2 +/- 2.6 g/dl; p < 0.01). The overall median survival was 7.1 years. Rai and Binet staging classifications and TTM score system retained their prognostic value in this CLL population. In addition, cases fulfilling criteria of "smoldering" CLL, had a very long survival (75% survival probability at 16 years). Life-expectancy of younger patients was significantly longer than that of older ones (median survival, 7.1 versus 4.1 years; p < 0.05). However, when the background mortality due to non-CLL related deaths (i.e., cardiovascular complications, epithelial cancers) was removed, survival advantage of young cases disappeared. In conclusion this study confirms that prognosis of young CLL patients can be easily assessed using the current well-defined criteria. Since age is not by itself a criterion for intensifying treatment, further efforts to identify those young CLL patients who qualify for more aggressive therapy should be made.

Entities:  

Mesh:

Year:  1994        PMID: 8005231     DOI: 10.1111/j.1600-0609.1994.tb00648.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Chronic lymphocytic leukemia in young individuals revisited.

Authors:  Julio Delgado; Neus Villamor
Journal:  Haematologica       Date:  2014-01       Impact factor: 9.941

2.  Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes.

Authors:  Sameer A Parikh; Kari G Rabe; Neil E Kay; Timothy G Call; Wei Ding; Susan M Schwager; Deborah A Bowen; Michael Conte; Diane F Jelinek; Susan L Slager; Tait D Shanafelt
Journal:  Haematologica       Date:  2013-08-02       Impact factor: 9.941

3.  Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.

Authors:  Hua-Jay J Cherng; Nadya Jammal; Shilpa Paul; Xuemei Wang; Koji Sasaki; Philip Thompson; Jan Burger; Alessandra Ferrajoli; Zeev Estrov; Susan O'Brien; Michael Keating; William G Wierda; Nitin Jain
Journal:  Br J Haematol       Date:  2021-05-10       Impact factor: 8.615

4.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.